trending Market Intelligence /marketintelligence/en/news-insights/trending/RZUqGitNBC5-YPZce0oW3g2 content esgSubNav
In This List

QIAGEN launches test for leukemia type in US

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


QIAGEN launches test for leukemia type in US

Qiagen NV launched its ipsogen JAK2 RGQ PCR kit in the U.S.

The test was cleared by the U.S. FDA for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from ethylenediaminetetraacetic acid whole blood.

QIAGEN's ipsogen is the first and only FDA-cleared qualitative in vitro diagnostic test for the JAK2 V617F mutation, which is important for the diagnosis of Polycythemia Vera.

Janus kinase 2 or JAK2 V617F is an acquired, somatic mutation present in the majority of patients with myeloproliferative cancer i.e. nearly 100% of patients with polycythemia vera and in about 50% of patients with essential thrombocytosis and primary myelofibrosis.